Transfer RNA and human disease by Jamie A. Abbott et al.
REVIEW ARTICLE
published: 03 June 2014
doi: 10.3389/fgene.2014.00158
Transfer RNA and human disease
Jamie A. Abbott , Christopher S. Francklyn and Susan M. Robey-Bond*
Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
Edited by:
Akio Kanai, Keio University, Japan
Reviewed by:
Lluís Ribas De Pouplana, IRB
Barcelona, Andorra
Anthony Antonellis, University of
Michigan, USA
*Correspondence:
Susan M. Robey-Bond, Department
of Biochemistry, College of
Medicine, University of Vermont,
Health Sciences Complex, B403
Given Bldg., 89 Beaumont Avenue,
Burlington, VT 05405, USA
e-mail: susan.robey-bond@uvm.edu
Pathological mutations in tRNA genes and tRNA processing enzymes are numerous and
result in very complicated clinical phenotypes. Mitochondrial tRNA (mt-tRNA) genes are
“hotspots” for pathological mutations and over 200 mt-tRNA mutations have been linked
to various disease states. Often these mutations prevent tRNA aminoacylation. Disrupting
this primary function affects protein synthesis and the expression, folding, and function
of oxidative phosphorylation enzymes. Mitochondrial tRNA mutations manifest in a wide
panoply of diseases related to cellular energetics, including COX deficiency (cytochrome C
oxidase), mitochondrial myopathy, MERRF (Myoclonic Epilepsy with Ragged Red Fibers),
and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes).
Diseases caused by mt-tRNA mutations can also affect very specific tissue types, as in the
case of neurosensory non-syndromic hearing loss and pigmentary retinopathy, diabetes
mellitus, and hypertrophic cardiomyopathy. Importantly, mitochondrial heteroplasmy plays
a role in disease severity and age of onset as well. Not surprisingly, mutations in enzymes
that modify cytoplasmic and mitochondrial tRNAs are also linked to a diverse range of
clinical phenotypes. In addition to compromised aminoacylation of the tRNAs, mutated
modifying enzymes can also impact tRNA expression and abundance, tRNAmodifications,
tRNA folding, and even tRNA maturation (e.g., splicing). Some of these pathological
mutations in tRNAs and processing enzymes are likely to affect non-canonical tRNA
functions, and contribute to the diseases without significantly impacting on translation.
This chapter will review recent literature on the relation of mitochondrial and cytoplasmic
tRNA, and enzymes that process tRNAs, to human disease. We explore the mechanisms
involved in the clinical presentation of these various diseases with an emphasis on
neurological disease.
Keywords: tRNA, neurodegenerative disease, localized translation, mitochondrial disease, aminoacyl-tRNA
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INTRODUCTION
Although the role of tRNA in translation has been known since
the late 1950’s, the first report linking a mutation in tRNA
to a human disease was published in 1990, when MELAS was
associated with a mutation in the mitochondrial tRNALeu gene
[mitochondrial tRNA Leu (L)] (MTTL1) (Kobayashi et al., 1990).
This report was followed by the demonstration that tRNALys is
associated with MERRF (Shoffner et al., 1990). Since then, mul-
tiple mutations in individual tRNA genes have been associated
with multiple diseases, and individual diseases have been found
to be caused by mutations in one of several tRNAs. Not unex-
pectedly, the penetrance and severity of disease caused by tRNA
mutations has been demonstrated to be unpredictable (Phizicky
and Hopper, 2010; Hurto, 2011; Suzuki et al., 2011; Tuller, 2012).
The primary role of tRNA is to deliver amino acids to the nascent
polypeptide chain during protein translation, a seemingly irre-
placeable function. Disease-causing mutations in tRNA, to date,
have been found only in mitochondrial tRNA, indicating that
the etiology of tRNA-linked diseases are tightly associated with
mitochondrial biology. How can different point mutations in the
same molecule lead to very different diseases? Do tRNAs play
additional roles in mitochondria or in the cell apart from trans-
lation, for example in organelle localization or replication, cell
death, membrane environment, or DNA replication (Dimauro
et al., 2013)? About 1700 mitochondrial proteins are coded in the
nuclear genome, and it is unknown howmutated mt-tRNAmight
interact with these.
Many macromolecules interact with tRNA in the cytosol as
well. The association of mutations in tRNA binding or processing
enzymes with disease is even more recent: tRNA splicing endonu-
clease mutations were found to cause pontocerebellar hypoplasia
as recently as 2008 (Budde et al., 2008). Mutations in the canoni-
cal tRNA partner, aminoacyl tRNA-synthetases (ARSs), were first
identified as causative agents of Charcot-Marie-Tooth in 2003
(Antonellis et al., 2003). The subject of ARSs and diseases has
also received attention, with a number of useful recent reviews
addressing various issues (Kim et al., 2011; Guo and Schimmel,
2013; Jia et al., 2013; Konovalova and Tyynismaa, 2013; Schwenzer
et al., 2013; Diodato et al., 2014). A major question yet to be
addressed is the localization of translation in neural cells, and how
tRNAmay be trafficked to ribosomes in distant regions (e.g., long
axons and synapses in neurons) of the cell.
In this review, we survey the known and emerging connec-
tions between tRNA and human diseases, and the role of its key
cellular partners in pathophysiology. We begin in the mitochon-
dria, as only mitochondrial tRNA mutations have been found,
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and briefly review how mitochondrial biology contributes to the
effects of tRNA mutations. Several tissue-specific diseases are
reviewed, followed by a discussion of potential therapeutics. Next,
we move into the cytoplasm to investigate tRNA interactions with
other molecules—specifically modifiers and splicing endonucle-
ases, followed by the role tRNA binding plays in regulating protein
synthesis. Finally we review the canonical role of tRNA interac-
tions with aminoacyl synthetases, with an emphasis on recent
disease discoveries.
MITOCHONDRIAL tRNA MUTATIONS AND DISEASE
MITOCHONDRIAL FUNCTIONAL BIOLOGY AND GENOMICS
Mitochondria perform the essential function of synthesizing ATP
in eukaryotic cells, and this cellular energy resource powers the
biosynthesis of key metabolites, mechanochemical and transport
functions, and a vast array of other activities. In addition to these
functional roles, the mitochondria also generate and regulate
the production of reactive oxygen species, as well as activate
important cellular pathways such as apoptosis. The 16.59 kb
double stranded circular mitochondrial genome is located within
the inner mitochondrial membrane, and encodes for a total of
37 genes. Thirteen of these encode for open reading frames that
comprise most of the subunits of the respiratory chain complexes
I (seven subunits), III (one subunit), IV (three subunits), and V
(two subunits). The remaining subunits of the respiratory chain
complex are encoded by genes located in the nuclear genome.
Two mitochondrial genes encode for ribosomal RNAs (rRNAs)
16S and 12S and the remaining 22 genes encode for the set
of mitochondrial transfer RNAs (mt-tRNA). All of the RNA
molecules necessary for mitochondrial translation are provided
for by the mitochondrial genome. However, many proteins
necessary to perform protein synthesis, including mitochondrial
aminoacyl tRNA synthetases (mt-ARS), ribosomal proteins, and
tRNA processing enzymes are encoded in the nuclear genome.
These are synthesized in the cytoplasm and subsequently
imported into the mitochondria.
MITOCHONDRIAL tRNA MUTATIONS AND DISEASE
It is well established that many different mt-tRNA mutations can
cause a wide range of human diseases. High-energy consuming
tissues such as muscular and nervous systems are particularly
affected by mitochondrial defects. Unlike chromosomal DNA
localized to the nucleus and subject to Mendelian inheritance,
mitochondrial DNA is inherited solely from the mother and
thousands of identical copies can exist per cell. Cells that carry
a homogeneous population of the mitochondrial genome, wild
type or mutated, are referred to as homoplasmic. A condition in
which more than one type of mitochondrial genome exists, either
in a cell, tissue or in an individual, is referred to as heteroplasmy.
Should a mutation spontaneously arise or be maternally inher-
ited, mitochondria carrying the pathogenic mutated mtDNA can
accumulate over the course of organismal development. When
the mutational load of a certain tissue type reaches a particu-
lar threshold, disease symptoms can become evident. Depending
on the mutation and the tissue, this threshold can vary from
50 to 90%. Mitochondrial diseases and their respective tRNA
mutations have been extensively cataloged, and the information
is available in a variety of useful databases (Putz et al., 2007;
Ruiz-Pesini et al., 2007). Past and recent examples of mt-tRNA
disease-causing mutations demonstrate that these tRNA genes
can affect mitochondrial protein synthesis, aminoacylation activ-
ity, and three-dimensional structure and folding of the tRNA in
Table 1 | Mitochondrial tRNA mutations and disease.
Mt-tRNA gene Mutation Disease Structural location Aberrant tRNA biology OMIM# References
MTTL1 A3243G MELAS anti-codon
(wobble position WP)
defect in taurine modification 540000 Latkany et al., 1999
MTTK A8344G MERRF anti-codon (WP) defect in taurine modification 545000 Shoffner et al., 1990
MTTI C4277T CMH1 DUH stem reduced expression in cardiac
tissue
192600 Taylor et al., 2003
A4300G Anticodon stem Perli et al., 2012
G4308A CPEO TC stem misfolding leads to improper 3′
end processing
590045 Schaller et al., 2011;
Souilem et al., 2011
A4302G Variable loop disrupt conserved base pairing Berardo et al., 2010
MTTH G12192 CM TC stem disrupt conserved base pairing 590040 Shin et al., 2000
G12183A NSHL
RP
TC stem disrupt conserved base pairing 500008 Crimi et al., 2003
T12201C NSHL Acceptor stem reduced expression of
functional tRNA
Yan et al., 2011
A12146G MELAS DHU stem misfolding 540000 Calvaruso et al., 2011
G12147A MELAS
MERRF
DHU stem misfolding and low abundance 540000
545000
Melone et al., 2004
MTTE G14685A C,SP,A TC stem disrupt conserved base pairing 590025 Lax et al., 2013
Disease abbreviations: MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy with ragged red fibers;
CMH1, cardiomyopathy familial hypertrophic; CPEO, Chronic progressive external ophthalmoplegia; CM, cardiomyopathy; NSHL, non-sensory hearing loss; RP,
Retinitis pigmentosa; C,SP,A, cataracts, spastic paraparesis, and ataxia.
Frontiers in Genetics | Non-Coding RNA June 2014 | Volume 5 | Article 158 | 2
Abbott et al. tRNA and human disease
the mitochondria (Table 1). Mitochondrial tRNA structures can
differ significantly from cytosolic tRNA (Florentz et al., 2003)
and many require specific complex modifications in order to
fold correctly. Here we will review some well-characterized and
recently reported mt-tRNA mutations, particularly as they relate
to neurobiology and specific human disease phenotypes.
MELAS AND MERRF
The two classic well-characterized diseases associated with mt-
tRNA mutations are mitochondrial encephalomyopathy, lac-
tic acidosis, and stroke-like episodes (MELAS) and myoclonic
epilepsy with ragged red fibers (MERRF). These are linked to
mutations in mt-tRNALeu and mt-tRNALys respectively (Suzuki
et al., 2011). Patients with MELAS present with seizures, recur-
rent headaches and vomiting, anorexia, exercise intolerance, and
proximal limb weakness; these are often seen early in child-
hood. Recurring stroke-like episodes can progressively impair
motor abilities, vision, hearing, and mentation. MELAS is pri-
marily caused by defects in respiratory chain complexes I and IV,
which lead to impaired oxidative phosphorylation. The A3243G
mutation, which encodes a mutation in the mt-tRNALeu wobble
position, is common among some 80% of MELAS patients (Goto
et al., 1990; Kobayashi et al., 1990). This mt-tRNALeu A3243G
mutation was initially confirmed in 5 patients with MELAS syn-
drome (Kirino et al., 2005). Interestingly, the A8344G mutation
associated with MERRF is also located in a wobble base position,
in this case in mt-tRNALys.
The effects of the mt-tRNALeu A3243G and mt-tRNALys
A8344G mutations were initially studied in cybrid cell lines
(Kirino et al., 2004) followed by further characterization using
mass spectrometry. Cybrid cells are created by fusion of cells that
are free of mitochondria (rho 0 cells) with donor platelets, or
by fusion of enucleated patient derived fibroblasts with osteosar-
coma cells that lack mtDNA. These cells thus possess mtDNA
from patients or controls in a control nuclear background.
Mutations linked to MELAS were subsequently shown to affect
the τm5U modification for mt-tRNALeu and the τm5s2U modi-
fication for mt-tRNALys at the wobble position in the anticodon
region (Yasukawa et al., 2000). These wobble position modifica-
tions are both essential for proper decoding by the mitochondrial
ribosome (Kirino et al., 2004). Additional details concerning the
biochemical affects of these taurine defective mutations have been
recently reviewed (Suzuki et al., 2011).
Other mt-tRNA mutations associated with MELAS and
MERRF phenotypes have been isolated in the gene encoding
mt-tRNAHis (Figure 1). In the first reports, the mutation was
found to be a heteroplasmic G12147A substitution (Melone et al.,
2004; Taylor et al., 2004), and analysis of muscle biopsy samples
revealed deficiency in cytochrome c oxidase (COX). The G12147A
mutation in the D-arm of the mt-tRNAHis molecule would be
expected to alter tRNA folding and abundance, leading to a spe-
cific decrease in the his-rich COXIII polypeptide, as well as a
general decrease in mitochondrial protein synthesis. Additionally,
a homoplasmic A12146G mutation was identified in another
MELAS patient (Calvaruso et al., 2011). As in the previous exam-
ple, an analysis of cybrid cells and patient muscle biopsy samples
showed that deficiencies in various respiratory chain complexes
enzymes were linked to the mt-tRNAHis mutation.
MITOCHONDRIAL BIOLOGY AND TISSUE SPECIFICITY OF DISEASE
Diseases related to mitochondrial tRNA mutations can manifest
in very specific tissue types, leading to complex phenotypes. For
example, the heart is heavily reliant on mitochondrial ATP pro-
duction for proper and synchronized muscle contraction, and is
thus particularly sensitive to mt-tRNA mutations. Animal mod-
els for heart failure and ischemia/reperfusion frequently display
morphological changes to mitochondria that would be expected
to exert negative impacts on the function of adult cardiac cells
(Piquereau et al., 2013). One such tRNA-linked cardiomyopa-
thy is the homoplasmic G12192A mt-tRNAHis mutation localized
to the loop of the TC arm, which was initially identified in
five patients (Figure 1) (Shin et al., 2000). Electron microscopy
imaging carried out on patient cardiomyocytes showed a loss of
sarcomere formation and an accumulation of mitochondria with
aberrant morphology.
Mutations associated with hypertrophic cardiomyopathy have
also been found in mt-tRNAIle (Figure 1) (Taylor et al., 2003;
Hollingsworth et al., 2012). For patients carrying these A4300G
and C4277T mt-tRNAIle mutations, the only symptom was
hypertrophic cardiomyopathy. However, detailed immunohisto-
chemistry and biochemical studies on the hearts of patients after
transplant surgery indicated a large proportion of COX-deficient
cardiomyocytes and defects in activity for respiratory chain com-
plexes I, III, and IV (Giordano et al., 2013). Also, there appeared
to be reduced expression of mt-tRNAIle in both left and right
ventricle samples from two patients compared with control mt-
tRNALeu. This suggests that the phenotype may arise from an
increasing number of COX-deficient cardiomyocytes; however,
the numbers of COX-deficient cells in cardiac muscle have been
shown to increase with age.
In addition to the classic MELAS and MERRF cases, muta-
tions in other mt-tRNAs are also linked to sensorineural defects.
A number of reports suggest that inner ear hair cells and their
connecting neuronal circuitry may be specifically affected by
mt-tRNA mutations. In one report, a late onset hearing impair-
ment in a Chinese family was linked to a T12201C mutation
in the acceptor arm of mt-tRNAHis, with the severity of hear-
ing impairment being linked to the degree of heteroplasmy
(Figure 1) (Yan et al., 2011). For this mutation, cellular and bio-
chemical analysis point to reduction in the levels of mt-tRNAHis
as being the source of reduced mitochondrial translation and
subsequent respiratory chain defects. Two related patients car-
rying a mt-tRNAHis inherited heteroplasmic G12183A mutation
both developed sensorineural pathology, presenting with visual
impairment around the average age of 9 (Crimi et al., 2003).
This mt-tRNAHis mutation alters a highly conserved base pair
in the TC arm and would most likely disrupt secondary struc-
ture. The older sibling had pigmentary retinopathy, neurosensory
deafness, and some muscle atrophy and ataxia, while the younger
sibling only experienced both visual and inner ear neurosensory
deficits. Interestingly, histochemical analysis of muscle biopsy tis-
sues for (COX/SDH) activity did not convincingly demonstrate a
complete COX deficiency.
Like the auditory system, the visual system is similarly sensi-
tive to mutations in mt-tRNA. For example, carriers of G12183A
mutation in mt-tRNAHis often present with a pigmentary
retinopathy that leads to photoreceptor degeneration, pigmentary
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FIGURE 1 | Structural analysis of mitochondrial tRNA and disease
causing mutations. Cloverleaf structure of mt-tRNAHis and mt-tRNAIle.
Mutations discussed in this review that cause neurosensory disease
(blue), cardiomyopathy (red), MELAS and MERRF (green), and other
pathological reported mutations not discussed in this review (gray).
The 3D mt-tRNAHis and mt-tRNAIle models were generated using
ModeRNA (Rother et al., 2011) of human mt-tRNA sequence (Sprinzl
and Vassilenko, 2005) alignments. Sequences were fit to structural
tRNA templates PDB: 1QTQ for mt-tRNAHis model and PDB: 1QUZ
for mt-tRNAIle.
deposits in the retina, and ultimately progressive loss of vision.
Specific muscles responsible for ocular movement are another
target in the visual system susceptible to mt-tRNA mutations.
Chronic progressive external ophthalmoplegia (CPEO) is a neu-
romuscular disorder characterized by the loss of extraocular
muscle mobility, which results in the inability to move the eyes.
In one case report, CPEO was found to be linked to a G4308A
mutation in the T-stem ofmt-tRNAIle; this substitution disrupts a
conserved GC base pair (Figure 1) (Schaller et al., 2011; Souilem
et al., 2011). While there was no evidence of maternal inheritance,
patient blood samples were homoplasmic for the wild type mt-
tRNAIle, and muscle tissue obtained by biopsy was heteroplasmic.
Analysis of the latter tissue indicated a link between the mutation
and respiratory chain defects, leading to abnormal mitochondrial
morphology. The G4308A substitution leads to a misfolded con-
formation that is likely to be incompatible with 3′ end processing
by tRNase Z. A G4302A mt-tRNAIle mutation located in the
variable arm was also found in a small number of CPEO patients
(Berardo et al., 2010). Despite a predicted disruption of a con-
served base pair in mt-tRNAIle, a muscle biopsy showed normal
function of all of the respiratory chain complex proteins (Berardo
et al., 2010). Of 22 pathogenic mutations observed in mt-tRNAIle,
nine cause CPEO, suggesting that mt-tRNAIle is a “hot-spot” for
CPEO. Most reported CPEO cases involving MTTI mutations are
heteroplasmic and restricted to skeletal muscle. MTTI mutations
exist that are primarily homoplasmic and can be found in various
tissue types. The molecular rationale for the tight linkage between
mt-tRNAIle and CPEO provides a fascinating research question
for future study.
In some systems, a tRNA-linked disorder that is primarily
a sensory defect may exert negative effects on additional brain
and motor neuron functions. One recent study reported that
the pathogenic G14685A mutation in mt-tRNAGlu affects both
visual and hearing systems (Lax et al., 2013). In this case, the 7
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year old affected subject suffered from cataracts, peripheral reti-
nal degeneration, and pigmentary retinopathy. This was followed
by bilateral sensorineural hearing impairment as an adolescent.
By the age of 40, the patient developed symptoms of spastic
paraparesis, ataxia, slurred speech, and incontinence. Subsequent
immunohistochemical (IHC) and biochemical analysis of mus-
cle and brain tissues collected post mortem indicated respira-
tory chain complex I deficiencies. Additional evidence suggested
that this heteroplasmic mutation arose sporadically, with brain
regions exhibiting the highest degree of heteroplasmy. The muta-
tion is located in the TC arm and substitutes a conserved
G-C Watson-Crick base pair; detailed functional studies have yet
to be conducted. To date there are 12 mutations in the MTTE
gene encoding mt-tRNAGlu that cause mitochondrial patholo-
gies with very different phenotypes, such as encephalomyopathy,
retinopathy, MELAS, and Leber’s hereditary optic neuropathy
(LHON).
MITOCHONDRIA IN NEUROBIOLOGY AND ADDITIONAL
CONSIDERATIONS FOR MITOCHONDRIAL DISEASE PHENOTYPES
While most cells are roughly spherical structures with diame-
ters in the range of micrometers to tens of micrometers, neurons
possess irregular structures with long dendrites and axons that
extend out from the soma at distances from millimeters to a
meter. The synapse has the highest energy consumption of the
neuron, and mitochondria are responsible for meeting this major
energy demand. Among the important ATP dependent processes
occurring at the synapse are vesicle exocytosis and endocyto-
sis, maintenance of membrane potential by ion channels, and
actin rearrangements of the cytoskeleton. Accordingly, synap-
tic mitochondria may be docked or anchored in these special-
ized compartments in order to execute these essential functions
(Court and Coleman, 2012; Sheng and Cai, 2012). Owing to
their ability to be transported along filamentous structures in the
cell, mitochondria are motile and can be readily localized at the
synapses and other high demand areas. Additionally, mitochon-
dria are dynamic and can undergo major structural changes such
as fusion, fission, and fragmentation.
Neuronal synapses are rich in mitochondria, both at the presy-
naptic and postsynaptic nerve terminals, and recent work suggests
that there may be differences between synaptic vs non-synaptic
mitochondria (Gillingwater and Wishart, 2013). In one model,
specialized synaptic mitochondria may be synthesized at the soma
and then trafficked to the synapse, where they adapt to the specific
demands of this specialized environment. Alternatively, synapse
specific mitochondria may be generated, selected for, and then
trafficked to the synapse. Other considerations are that the mito-
chondria at the synapse are “older” and therefore not as efficient
or that synaptic mitochondria may be synthesized in axons and
would be closer to their destination at the axonal synapse (Amiri
and Hollenbeck, 2008; Yarana et al., 2012).
These issues bear on the investigation of the above described
neurobiological phenotypes, where defects arising from mt-
tRNA mutation or mt-ARS mutations cause losses of mito-
chondrial function that are concentrated at the synapse (Baloh,
2008). While past work underscores how the altered struc-
ture, expression, or lack of tRNA modifications resulting from
mt-tRNA mutations may disrupt protein translation (Florentz
et al., 2003), the apparent tissue specific phenotype of many of
these pathophysiological mutations remains to be elucidated. For
diseases that affect basic neurobiologial functions, mtDNA tRNA
mutations may affect processes beyond mitochondrial transla-
tion, including the mitochondrial inner membrane (MIM) lipid
environment, dynamics, maintenance, and replication machinery
(Dimauro et al., 2013). Mutations in mitofusin, a protein respon-
sible for mitochondrial fusion and fission, cause the periph-
eral neuropathy disease Charcot-Marie-Tooth (CMT) type 2A
(Zuchner et al., 2004; Kijima et al., 2005). In a zebrafish model,
the loss-of-function mutation demonstrated that indeed trans-
port of mitochondria along the axon is disrupted and may be the
contributing factor in the CMT2A phenotype (Chapman et al.,
2013). The issue of how mitochondrial movement may be reg-
ulated, and the role of the other essential factors in that process
is discussed in detail elsewhere (Schwarz, 2013). Clearly, how
specific mt-tRNA mutations affect biological functions of mito-
chondria is only beginning to be understood, and will remain a
fertile area of research for the foreseeable future.
FUTURE MITOCHONDRIAL RESEARCH STRATEGIES AND POTENTIAL
THERAPEUTIC APPROACHES
Therapeutic progress toward cures for mitochondrial diseases has
been slowed by the complex genetics associated with mitochon-
drial inheritance. For example, a mother with a low degree of
heteroplasmy in her mtDNA can transmit a higher level of hetero-
plasmy to her children, a process referred to as a “mitochondrial
bottleneck.” Current efforts to better understand mitochondrial
inheritance and the pathophysiology of mt-tRNA mutations are
benefitting from both traditional systems like cybrid cells, and
from induced pluripotent stem cell (iPScs) technology. iPScs
can be challenging to develop if only specific tissues of affected
patients carry the mt-tRNA mutation. Mito-mouse models have
been generated to recapitulate pathogenic mitochondrial DNA
mutations (Inoue et al., 2000). Recently this group of investigators
generated a MERRF mito-mouse model incorporating the mt-
tRNALys G7731A mutation (Shimizu et al., 2014), arguably the
first of many such models. The animals generated carried vary-
ing levels of the mt-tRNALys G7731A mutation, and these levels
correlated with the severity of the disease phenotype. Selection
of oocytes that carried low amounts of the mt-tRNALys G7731A
mtDNA mutation produced animals that appeared to be phe-
notypically normal. This work highlights the promise of this
technology in generating future mt-tRNA disease models.
Other therapeutic options under active investigation for mito-
chondrial diseases include cytoplasmic transfer, gene therapy,
or even eliminating dysfunctional mitochondria by altering
mitochondrial dynamics to favor quality control mechanisms
(Dimauro et al., 2013). In yeast, overexpression of the corre-
sponding mt-ARS provides a rescue mechanism for pathological
mt-tRNA mutations (De Luca et al., 2006). In human cells that
model MELAS, the mt-tRNALeu A3243G mutation can be res-
cued by over expression of mt-LeuRS (Park et al., 2008; Li and
Guan, 2010). Furthermore, in yeast models of some mt-tRNALeu,
mt-tRNAVal, and mt-tRNAIle mutations, overexpression of the
carboxy-terminal domain of mt-LeuRS is sufficient to rescue the
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respiratory chain defects (Francisci et al., 2011). In human cybrid
cells overexpression of mt-LeuRS, mt-ValRS, and mt-IleRS has
been shown to rescue pathogenic mutations in mt-tRNAIle (Perli
et al., 2014). How the mt-LeuRS C-terminal domain is able to
specifically rescue the defect associated with the mutant tRNA
remains to be determined, but may involve direct interactions
with mt-tRNAIle (Perli et al., 2014).
Mitochondrial gene replacement offers one of the most dra-
matic routes to treatment ofmitochondrial disease. A recent note-
worthy experiment featured the transfer of the nuclear genome
from a primate oocyte to an enucleated oocyte of another pri-
mate containing only mitochondria (Tachibana et al., 2009). The
oocytes generated contained the nuclear genome from two par-
ents but mitochondria from the donor; when implanted in pseu-
dopregnant mother they were able to successfully produce healthy
rhesus macaque offspring. Not surprisingly, human oocyte mito-
chondrial genome transfer is under way (Amato et al., 2014),
although research in the U.S. likely to lag relative to Europe, owing
to U.S. funding restrictions on human embryo research. While
this three-parent in vitro fertilization shows tremendous promise
as means to produce a child without mitochondrial DNA muta-
tions that retains both parents’ nuclear genome, the approach
does not address curing existing patients with mitochondrial
disease, or treating mtDNA mutations that arise spontaneously.
CYTOPLASMIC tRNA CELLULAR INTERACTIONS AND
DISEASE
DISEASE-ASSOCIATED CYTOPLASMIC tRNA MUTATIONS ARE NOT
OBSERVED
The human genome contains approximately 500 tRNA genes,
including gene duplications (Lowe and Eddy, 1997; Schattner
et al., 2005). However, there are only 61 anticodons specified by
the triplet code, so many of these identified tRNA genes share the
same anticodon but differ in sequence elsewhere. Remarkably, a
human disease that is linked to a mutation in a cytoplasmic tRNA
has not yet been reported, and this may be a direct result of the
presence of multiple paralogs of the gene encoding each cytoplas-
mic tRNA molecule. The tRNA for each anticodon, save a single
gene for tRNATyr (ATA), is encoded by as many as 32 paralo-
gous genes (Chan and Lowe, 2009). The process of generating
each mature tRNA is a complex sequence of events that includes
gene transcription, splicing, 5′ and 3′ end processing, CCA addi-
tion, transportation, and aminoacylation (Hopper et al., 2010).
Errors in this sequence arising from mutations in the genes
encoding the enzymes that bind and process cytoplasmic tRNA
molecules are known, and account for a number of reported dis-
eases. Furthermore, a growing body of literature suggests that
tRNAmolecules possess previously unrecognized biological func-
tions in eukaryotes which are not fully understood (Phizicky and
Hopper, 2010), and that may be perturbed by disruptions of
the tRNA-protein interaction. Some of these biological functions
include regulation of cellular apoptosis (Mei et al., 2010; Hou and
Yang, 2013). See Figure 2 for a schematic overview.
ROLE FOR tRNA MODIFICATIONS IN DISEASE
The tRNAs found in higher eukaryotic species are more highly
modified relative to prokaryotic and viral tRNA, a distinction that
may have arisen from multiple selection pressures. Consequently,
various human diseases can arise from improperly modified
tRNAmolecules (Torres et al., 2014). One element may have been
to facilitate immune system discrimination of foreign tRNAs from
self-tRNAs (Hanada et al., 2013), discussed below. Modifications
of tRNA molecules can serve to support proper folding or
facilitate recognition by other interacting enzymes. Classically,
impaired modification of mt-tRNA has been associated with
reduced recognition by ARS. More recently, methylation of tRNA
has been linked to immune response stimulation (or suppres-
sion), via toll-like receptor 7 (TLR7) (Kariko et al., 2005; Robbins
et al., 2007; Hamm et al., 2010; Jockel et al., 2012). Toll-like recep-
tor activation initiates intracellular signaling events in immune
cells by stimulating the release of cytokine type I interferon
(IFN). Immune cell TLR7 stimulation can also occur when either
viral or bacterial single-stranded RNA or siRNA binds to the
receptor in the endosome or cytoplasm (Blasius and Beutler,
2010) and results in IFN production (Takeuchi and Akira, 2010).
Purified tRNA from various bacterial species was used to test
the immunostimulatory potential in human peripheral blood
mononucleated cells (PBMCs). Interestingly, tRNA purified from
T.thermophilus and E.coli did not stimulate IFN-α production
from PBMCs. Differences in specific tRNA methylation sites
between bacterial species may thus be responsible for loss of
TLR7 stimulation and IFN-α production. Isolated tRNA from
E.coli species lacking a specific tRNA-methyltransferase, the trmH
encoded Gm18-2’-O-methyltransferase, acquired immunostimu-
lation of TLR7. Curiously, only 7 of 42 tRNAs are Gm18 mod-
ified in E.coli (Sprinzl and Vassilenko, 2005). Modified Gm18
tRNA mediated inhibition of TLR7 stimulation in mouse FLT3L-
induced dendritic cells (DCs) occurs in a dose dependent manner.
Also, Gm18-modified tRNA can inhibit viral influenza a virus
(IAV) TLR7 stimulation. These experiments demonstrate that
Gm18-modified tRNA can act as an antagonist against TLR7-
mediated production of IFN-α. In a similar investigation, the
2′-O-methylated Gm18 of yeast tRNAPhe and tRNATyr was also
found to exert a suppressive affect on the immune response via
TLR7 antagonism (Gehrig et al., 2012).
tRNA SPLICING AND DISEASE
After transcription by polymerase III, many pre-tRNA molecules
undergo post-transcriptional alterations to produce a mature
product that can be utilized for translation. Initial transcripts are
cleaved by the nucleases tRNaseZ and RNase P, which act to form
the 3′ and 5′ ends, respectively. Additional modifications aremade
in the nucleus before transportation into the cytoplasm where, if
necessary, alternative splicing can occur. Overall, RNA editing and
alternative splicing is highest in the brain compared with other
tissues (Norris and Calarco, 2012; Tariq and Jantsch, 2012). In
humans the spleen has the highest expression of tRNA followed by
the brain (Dittmar et al., 2006). As tRNA splicing has an impor-
tant role in the central nervous system (CNS) it is not surprising
that mutations in the splicing machinery can cause specific CNS
diseases. In the human genome there are 32 intron-containing
tRNAs (Lowe and Eddy, 1997).
Pontocerebellar hypoplasia (PCH) is a heterogeneous neu-
rodegenerative disorder characterized by defective growth,
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FIGURE 2 | Transfer RNA interactions and associated diseases.
Cellular pathways of tRNA and interacting proteins and enzymes.
Diseases discussed in this review are italicized in red. Figure was
generated using BioDraw Ultra 12.0. Disease abbreviations:
Charcot-Marie-Tooth disease (CMT), pulmonary veno-occlusive disease
(PVOD), pontocerebellar hypoplasia (PCH). Enzyme abbreviations: AARS,
aminoacyl-tRNA synthetase; CLP1, cleavage and polyadenylation factor I
subunit 1; TSEN, tRNA-splicing endonuclease complex; IFIT,
interferon-induced tetratricopeptide repeat; GCN2, general control
nonderepressible 2.
development, and function of the brainstem and cerebellum.
Symptoms of PCH include microcephaly, seizures, hypotonia,
hyper-reflexia, and optic atrophy. Magnetic resonance imaging
(MRI) of patient brain tissue shows immature development of
the cerebellum as well as mild structural defects (Budde et al.,
2008). Mutations in the tRNA-splicing endonuclease complex
(TSEN2, TSEN15, TSEN34, and TSEN54) were identified in mul-
tiple PCH2 and PCH4 patients. An A307S substitution in TSEN54
that is predicted to be non-catalytic appeared in multiple cases
(Budde et al., 2008). Notably, TSEN54 is highly expressed in
the pons and cerebellar dentate regions of the developing brain
(Budde et al., 2008). Two mutations that encode Y309C and
R58W substitutions in the catalytic subunits TSEN2 and TSEN34,
respectively, were also identified. As these are unlikely to com-
pletely abolish endonuclease activity, altered tRNA splicing may
not be the sole cause of the phenotype. Alternatively, these might
compromise mRNA 3′ end formation or a function of TSEN54
other than tRNA editing, leading to insufficient protein synthesis
of specific brain regions during development.
A mutation in a kinase that associates with the TSEN splic-
ing complex affects tRNA processing and is embryonic lethal.
Cleavage and polyadenylation factor I subunit 1 (CLP1) is amam-
malian RNA kinase capable of phosphorylating the 5′hydroxyl
of double and single stranded RNA and has a role in mRNA
3′-end formation (Weitzer and Martinez, 2007; Ramirez et al.,
2008). CLP1 associates with the TSEN splicing complex and a
role for CLP1 in tRNA processing has recently been demon-
strated (Hanada et al., 2013). A mouse model for a CLP1
mutation that abolishes kinase activity was used to examine
the phenotypic outcome. Neonatal death of the CPL1 mutant
mice was a consequence of respiratory failure and non-viable
mouse pups showed a substantial loss of motor neurons. An
accumulation of novel tyrosine tRNA fragments derived from
pre-tRNA was observed in the brain, muscle, kidney, heart, and
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liver, while mature tRNA levels remained normal. Recent ini-
tial biochemical characterization of CLP1 as part of the TSEN
tRNA splicing complex has demonstrated that ATP is not required
for CLP1 binding to the complex but CLP1 ATP hydrolysis is
required for proper pre-tRNA cleavage (Hanada et al., 2013).
Also, efficient pre-tRNA cleavage is protein phosphorylation
dependent.
tRNA FRAGMENTS AND DISEASE
As shown above, tRNA fragments can be associated with disease
(Fu et al., 2009). Angiogenin is a ribonuclease that is essential
in blood vessel growth and development (Shapiro and Vallee,
1987) and has a role in angiogenesis (Shapiro and Vallee, 1989).
Interestingly, in vitro full length tRNAs were shown to be sub-
strates for angiogenin (Saxena et al., 1992). Under a broad range
of stresses that include heat shock, hypoxia, hypothermia, and
nutritional deprivation stress-induced small RNAs (tiRNAs) of
30–40 nucleotides can be generated by cleavage in the anticodon
region (Fu et al., 2009). Mature tRNA fragments derived from
tRNAGly, tRNAGlu, tRNAVal, tRNAArg have been identified in
human fetal liver, mouse liver and heart tissue, and various cells
lines. Significantly, reduction in angiogenin levels by siRNA treat-
ment has been shown to decrease the accumulation of tRNAVal
halves under stress conditions. The production of tRNA halves
appears to cause translational arrest by amechanism distinct from
the better-known eIF2α dependent phosphorylation (Yamasaki
et al., 2009). Of further interest, only the 5′ generated fragments
are associated with translational arrest, and 5′-tiRNACys and 5′-
tiRNAAla are the most potent repressors of translation relative to
other 5′-tiRNAs (Ivanov et al., 2011). The molecular mechanism
of tiRNA translational repression has been linked to displacement
of eIFG/A from mRNA. This proposed translational repression
mechanism inmammalian cells involves the formation of a tiRNA
and protein Y box binding protein 1 (YB-1) complex that asso-
ciates with m7G cap of mRNA to inhibit eIFG/A from initiating
translation (Ivanov et al., 2011).
tRNA BINDING PROTEINS DURING CELLULAR STRESS CAUSE DISEASE
Translation in eukaryotes can be attenuated in response to diverse
environmental stresses, including nutrient deprivation, iron lim-
itation, protein export blockage, viral infection, UV irradiation
and others. The physiological responses to these environmen-
tal challenges are coordinated by members of the eIF2α kinase
family, which possess the ability to phosphorylate eIF2α when
activated (Wek et al., 2006; Baird and Wek, 2012). The GCN2
kinase serves as the principal response to nutrient limitation,
and reveals a special role for tRNA in its regulatory mechanism
(Harding et al., 2003; Wek et al., 2006). In response to amino acid
starvation, uncharged tRNA specifically activates GCN2, by virtue
of binding to a HisRS-like domain. GCN2 is a serine-threonine
kinase and, in addition to its kinase domain, also contains a
HisRS like domain(Wek et al., 1995). The binding of tRNA to the
HisRS-like domain induces a conformational change that subse-
quently activates the kinase domain (Dong et al., 2000; Qiu et al.,
2001).
Animals lack the ability to synthesize 9 of the canonical 20
amino acids found in proteins. When an animal consumes an
amino acid imbalanced diet, the deficiency in one or more
essential amino acids decreases the concentration of essential
amino acids in the blood stream. This elicits a short-term
response, mainly controlled by the brain, and a longer-term
response, largely controlled by the liver. The short term and brain
specific response is based on special properties of the anterior
piriform cortex, a region of the brain that functions in olfac-
tion (Hao et al., 2005). GCN2 specifically expressed in this region
acts as a special sensor of indispensible (essential) amino acids,
regulating feeding behavior through its control of activating tran-
scription factor 4 (ATF-4), the mammalian homolog of GCN4
(Harding et al., 2000; Hao et al., 2005). When rats are fed an IAA-
deficient diet, the buildup of uncharged tRNA leads to activation
of GCN2 (Rudell et al., 2011). This causes an adverse response,
such that the animals cease feeding and search for new food
sources that have a complete panel of essential amino acids. The
neural circuitry for this behavior is only partially understood, but
is being actively investigated (Maurin et al., 2014).
In addition to nutrient deprivation, the expression of GCN2
in the brain has recently been shown to participate in the control
of long-term potentiation (LTP), a major component of synaptic
plasticity associated with the enhancement of signaling between
neurons. The late phase of LTP (L-LTP) is dependent on gene
expression and de novo protein synthesis. A key factor in long
term memory in general and LTP in particular is the repressor of
cAMP responsive element binding protein (CREB), which plays a
direct role in L-LTP, learning, and memory (Costa-Mattioli et al.,
2005). Notably, CREB expression is negatively regulated by ATF4,
which is controlled by GCN2. CREB, ATF4, and GCN2 establish
a circuit in which perturbations of translational initiation lead to
changes in both electrophysiological measurements of LTP and
altered performance in quantitative tests of memory, such as the
Morris water maze test. The expression of ATF4 is down regulated
in GCN2−/− animals, resulting in increased spatial memory after
weak training, but poorer spatial memory after extensive train-
ing (Costa-Mattioli et al., 2005). Notably, the switch from short
term to long synaptic plasticity and memory is dependent on
eIF2α phosphorylation, which is a direct consequence of GCN2
activity (Costa-Mattioli et al., 2007). Collectively, these obser-
vations underscore the role of protein synthesis control in the
establishment of memory. GCN2 also serves a function in proper
neurobiology development and is down regulated by inhibition
from imprinted and ancient gene protein homolog (IMPACT) in
order to promote protein synthesis and neurite growth (Pereira
et al., 2005; Roffe et al., 2013).
Recently, two reports linked inherited mutations in the gene
encoding GCN2, EIF2AK4, with complex phenotypes arising
from vascular pathology. In the first report (Eyries et al., 2014),
numerous mutations in the EIF2AK4 gene were linked to pul-
monary veno-occlusive disease (PVOD), which is characterized
by obstruction and blockage of pulmonary veins by fibrous, col-
lagen rich tissue. PVOD is characterized by low diffusing capacity
for carbon monoxide, septal line and lymph node enlargement,
as well as occult alveolar hemorrhage (Eyries et al., 2014). By
whole-exome sequencing, subjects in 13 families with the dis-
ease were found to possess multiple mutations in the EIF2AK4
gene, in both the homozygous and compound heterozygous state
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(Eyries et al., 2014). Age of onset in patients varied widely from
10 to 50 years of age. Most mutations encoded stop codons in
the GCN2 open reading frame, but at least two encoded mis-
sense mutations that mapped to conserved residues in the kinase
domain.
In a second study (Best et al., 2014), inherited and spo-
radic mutations in the EIF2AK4 gene were linked to pulmonary
capillary hemangiomatosis (PCH), a progressive and eventu-
ally fatal disease characterized by capillary proliferation and
invasion into alveolar septa and the bronchial wall. Symptoms
included pulmonary hypertension, fatigue, cough, weight loss,
and dyspnea. Exome sequencing between related individuals of
patients with PCH determined that mutations in EIFAK4 are
responsible for the autosomal recessive PCH phenotype. Both
affected siblings carried the same compound heterozygous muta-
tions for which the parents were heterozygous carries, a non-
sense 3438C>T (Arg1150X) mutation and frameshift 1153dupG
(Val385fs) mutation (Best et al., 2014). Owing to clinical simil-
iarity and related immunohistochemistry, PVOD is grouped with
PCH, (Langleben et al., 1988; Humbert et al., 1998) and it is
likely that these are different clinical description of the same basic
pathophysiology. There is insufficient information to rationalize
the connection between GCN2 and lung vascular pathophysiol-
ogy, but an interesting hypothesis is that mutations that com-
promise GCN2 stress response function may expose pulmonary
environment to more oxidative stress, which may predispose both
mouse pulmonary hypertensive models and human subjects to
pulmonary hypertension (Eyries et al., 2014).
Many studies have demonstrated the importance of GCN2
regulation during cellular stress (Grallert and Boye, 2013). In
addition to its link in the pulmonary diseases described above
GCN2 has an essential role in supporting tumor cell growth (Wek
and Staschke, 2010) and proliferation (Ye et al., 2010, 2012). An
alternative hypothesis is that GCN2 interacts with SMAD4 and
SMAD1 family members, which have been implicated in signal-
ing pathways associated with bone morphogenic protein (BMP)
signaling, which is also genetically linked to pulmonary arte-
rial hypertensive disorders (West et al., 2004). As whole genome
sequencing becomes more affordable and widely available, it is
likely that other clinical manifestations will be linked to altered
GCN2 function, perhaps even with the neurobiological context
suggested by the previously described work on nutrition sensing
and LTP formation.
THE MOLECULAR BIOLOGY OF TRANSLATION IN NEURONS AND
PROTEIN SYNTHETIC MACHINERY
Neurons possess distinct compartments, axons and dendrites col-
lectively referred to as neurites, which are packed with specific
sets of proteins to facilitate neuronal function. Positioning mRNA
in these specialized compartments for protein synthesis allows
neurons to remodel neurites during outgrowth, regulate synthesis
of receptor subunits altering the synaptic proteome, and prevent
uncontrolled recurring excitation (Turrigiano, 2011; Penn et al.,
2013). A number of significant neurodegenerative diseases, such
as amyotrophic lateral sclerosis (ALS), fragile X tremor ataxia
syndrome (FXTAS), and myotonic dystrophy apparently involve
dysfunctional messenger RNA (mRNA) localization (Ramaswami
et al., 2013). Neuronal transport of mRNA from the soma to
axons and dendrites is in part dependent on a family of pro-
teins referred to as RNA binding proteins (RBPs) (Darnell,
2013). Localized translation can provide efficient increases in
local protein concentrations, and regulate both immediate and
delayed responses in neurons (Holt and Schuman, 2013). As
our understanding of localized translation grows to include
mRNA metabolism and spatial regulation, our understanding
of how the other components of protein synthesis machinery
are trafficked and spatially regulated in neurons should also
expand.
In most cells, tRNA comprises approximately 12% of total
RNA (Pace et al., 1970). Currently, tRNA molecules undergo
selective transportation and localization in order for accurate pro-
tein synthesis to occur in eukaryotic cells. After transcription
by RNA Pol III some tRNA molecules can be cleaved and post-
transcriptionally modified in the nucleus (Hopper and Phizicky,
2003) before being transported into the cytoplasm for protein
synthesis. Cytoplasmic tRNA can undergo retrograde transporta-
tion from the cytoplasm back into the nucleus (Rubio and
Hopper, 2011). This mechanism may help control the rate of
protein synthesis by sequestering tRNA into the nucleus during
times of cellular stress. Evidence of nuclear accumulation of tRNA
has been shown to occur within 15min after glucose starvation
(Whitney et al., 2007). Further indication shows that this appears
to be linked to PKA activation and signaling but GCN2 pathway
independent (Whitney et al., 2007). Amino acid starvation can
also drive accumulation of tRNA into the nucleus (Shaheen and
Hopper, 2005).
Given the emerging role of tRNA localization, it may be
noteworthy that the interferon-induced tetratricopeptide repeat
(IFIT) protein IFIT5 was recently shown to have tRNA bind-
ing properties (Katibah et al., 2013). IFIT5 was shown to bind
RNA with 5′phosphate caps including initiator methionine iMet,
tRNAVal, tRNAGly, and tRNALys. IFIT5 appears to coimmuno-
precipitate with shorter fragments rather than full-length tRNA
molecules, suggesting it may help target tRNAs for degradation.
IFIT5 can also bind actin, and localize to the cellular surface.
In the same way that mRNA is preferentially trafficked to den-
drites and axons (Wang et al., 2007), tRNA molecules may also
be recruited to active sites of localized translation, setting the
stage for translation to occur. Recently, single molecule stud-
ies using fluorescence in situ hybridization (FISH) showed that
β-actin mRNA and ribosome mobilization to axons is stimulus
induced, and that the β-actin mRNA becomes more available
to translation machinery after synaptic stimulation (Buxbaum
et al., 2014). This same group later developed a transgenic mouse
with in vivo labeled β-actin mRNA (Park et al., 2014). β-actin
mRNA appeared as part of granules and often multiple copies of
the transcript were found in granules localized to dendrites. The
movement of endogenous β-actin mRNA containing granules
from the soma to the synapse was subsequently estimated to occur
at a speed of 1.3μm/s (Park et al., 2014). Comparably, IFT5 actin
localization and tRNA binding activity could serve as a potential
mechanism to inhibit localized translation, but IFIT5 localization
to actin structures was shown to also be independent of RNA
binding. However, there may still be potential mechanisms in
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place to spatially regulate tRNA localization within neurons that
remain to be elucidated.
AMINOACYL-tRNA SYNTHETASES AND DISEASE
OVERVIEW OF AMINOACYL-tRNA SYNTHETASES
Aminoacyl-tRNA synthetases (ARSs) catalyze the attachment of
amino acids to cognate tRNA, a key reaction that contributes to
the accuracy of protein synthesis. ARSs can be divided into two
distinct classes (Carter, 1993; Ibba and Soll, 2001, 2004). Class
I enzymes are, with the exception of TyrRS and TrpRS, prin-
cipally monomeric, contain a Rossman fold catalytic domain,
and aminoacylate the 2′ hydroxyl of the terminal adenosine of
their cognate tRNAs. Class II ARSs typically form dimers and
tetramers, and feature a catalytic domain organized around an
antiparallel beta sheet fold flanked by alpha helices. The class
II enzymes couple the amino acid moiety to the 3′ hydroxyl of
the tRNA’s terminal adenosine. A typical animal cell contains
37 cytoplasmic and mitochondrial synthetase genes, all of which
are encoded on nuclear chromosomes. Mitochondrial synthetases
are given the same name as cytosolic synthetases, appended
with the numeral 2 (e.g., HARS and HARS2). Collectively,
they ensure accurate and efficient protein synthesis under a
broad range of conditions and, significantly in multiple cellular
compartments.
Pathological mutations have been identified in 10 of the genes
encoding mt-ARSs (Schwenzer et al., 2013). The first of these
was identified in the DARS2 gene, which encodes mitochondrial
aspartyl-tRNA synthetase (Scheper et al., 2007). Currently, patho-
logical mutations that cause human diseases have been identified
in ten genes that encode cytoplasmic tRNA-synthetases. The first
cytoplasmic ARS mutation associated with a human disease,
Charcot-Marie-Tooth, was discovered in glycyl-tRNA synthetase
(GARS) (Antonellis et al., 2003). Here, we will focus specifi-
cally on aminoacyl tRNA synthetase mutations that affect the
peripheral nervous system, sensorineural tissues, and the central
nervous system (Table 2).
AMINOACYL-tRNA SYNTHETASES AND PERIPHERAL NEUROPATHIES
Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral
neuropathy that manifests as progressive degeneration of distal
motor and sensory neurons, leading ultimately to muscle weak-
ness and atrophy of the legs and hands/arms. The various forms of
CMT can be further categorized into either demyelinating type 1,
which features defects in the myelin sheath surrounding periph-
eral nerves, and axonal type 2, which results in abnormalities in
the axon of the peripheral nerve. Nerve conduction studies and
electromyography (EMG) examination of patients with CMT are
typically abnormal. While more than 80 genes have been linked to
CMT (Timmerman et al., 2014), 30 mutations in ARS genes are
associated with the intermediate and axonal autosomal dominant
and intermediate autosomal recessive forms of the disease (Yao
and Fox, 2013).








KARS_601421 613641 Anti-codon binding domain
Active site





Antonellis et al., 2003
AARS_601065 613287 Editing domain CMT2N Latour et al., 2010
YARS_603623 608323 Catalytic domain DI-CMTC Jordanova et al., 2006
HARS_142810 NC Dimer interface CMT Vester et al., 2013
HARS2_600783 614926 Catalytic domain Perrault syndrome Pierce et al., 2011
LARS2_604544 615300 Catalytic domain
C-terminal domain
Perrault syndrome Pierce et al., 2013
HARS_142810 614504 Anti-codon binding domain Usher syndrome IIIB Puffenberger et al., 2012
KARS_601421 613916 Anti-codon binding domain ARNSHI Santos-Cortez et al., 2013
DARS_603084 615281 Catalytic domain HBSL Taft et al., 2013
DARS2_610956 611105 Multiple LBSL Scheper et al., 2007
RARS2_611524 611523 Lacking exon 2 PCH Edvardson et al., 2007
QARS_603727 ONA Catalytic domain
N-terminal domain
MCPH Zhang et al., 2014
MARS_156560 NC C-terminal domain
N-terminal domain
HSP Novarino et al., 2014
EARS2_612799 614924 Multiple LTBL Steenweg et al., 2012
AIMP2_600859 168600 na Parkinson’s disease Lee et al., 2013
NC, not confirmed; ONA, OMIM not assigned; Na, not applicable; CMT, Charcot-Marie-Tooth disease; DHMN5A, distal spinal muscular atrophy type V; ARNSHI,
autosomal recessive non-syndromic hearing impairment; HBSL, hypomyelination with brain stem and spinal cord involvement and leg spasticity; LBSL, leukoen-
cephalopathy with brainstem and spinal cord involvement and elevated lactate; PCH, pontocerebellar hypoplasia; MCPH, autosomal recessive primary microcephaly;
HSP, hereditary spastic paraplegia; LTBL, leukoencephalopathy with thalamus and brainstem involvement and high lactate.
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The first cytoplasmic ARS to be linked to CMT was glycyl-
tRNA synthetase (GARS) (Antonellis et al., 2003). Since that
initial report, mutations in the genes encoding four addi-
tional aminoacyl-tRNA synthetases have been linked to CMT
(Wallen and Antonellis, 2013). Mutations in the GARS gene
can cause both CMT2D and distal spinal muscular atrophy
type V (DHMN5A) (Antonellis et al., 2003). It is likely signif-
icant that the synthetase enzyme encoded by the GARS gene
is obliged to function in both the cytoplasmic and mitochon-
drial compartments. Similar to other class II enzymes, GARS
is an obligate dimer, and several of the mutant substitutions
linked to CMT alter residues located at the dimer interface (Xie
et al., 2007). Some of these have been shown to either weaken
or strengthen dimer formation (Xie et al., 2007). Additionally,
it may also be relevant that wild type protein forms punctate
structures (granules) in neurite projections, a property lost in
some of the GARS CMT mutants (Antonellis et al., 2006). Other
in vitro models of CMT GARS mutations also demonstrate a
defect in localization to neurite like projections in a transfected
neuroblastoma cell line (Nangle et al., 2007). It is not clear
whether the phenotype is related solely to the cytoplasmic or
mitochondrial distribution of GARS, or both. However, cytoplas-
mic ARS gene mutations associated with peripheral neuropathies
(Wallen and Antonellis, 2013) indicate that dysfunctional mito-
chondrial protein translation is not the primary cause of these
phenotypes.
A unique Drosophila model was created to examine the effects
of the GARS CMT2Dmutation on two different types of neurons,
olfactory projection neurons and mushroom body γ neurons
(Chihara et al., 2007). These represent two different CNS neu-
ron populations and differ in development, morphology, and
circuitry. The olfactory projection neurons showed severe defects
in dendritic morphology but few axonal defects. However, mush-
room body γ neurons had defects in both axon and dendritic
morphology. Interestingly, as GARS is cytoplasmic and mito-
chondrial, individual disruption of cytoplasmic protein synthesis
caused large defects in axonal and dendritic nerve end branching,
while disruption of mitochondrial protein synthesis led to more
dendritic nerve end branching than axonal. TheDrosophilaGARS
mutations could be rescued by expression of human WT GARS.
However, CMT2D mutations E71G and L129P could not rescue
the defective neuronal projections and hence are loss of function
mutations.
Mouse models of GARS CMT mutations have shed some
light on the possible pathological mechanism for which ARSs
can cause peripheral neuropathy. Interestingly, there did not
appear to be significant mislocalization of GARS protein or
change in GARS granule formation in the CMT2Dmouse model,
GARSNmf294/+ (Stum et al., 2011). The GARSNmf294/+ mouse
model of CMT2D also showed defects in the neuromuscular
junction (NMJ), reduced axon diameter, and sensory and periph-
eral axonal loss but no myelination defects. Importantly, this
mutation does not cause a substantial loss of primary aminoa-
cylation function (Seburn et al., 2006). More recent studies of
GARSNmf294/+ mice have shown that peripheral neuropathy is
not caused by reduced neuronal connectivity to distal muscle
fibers but that defects and denervation commonly observed at
NMJs corresponds to inappropriate maturation process at distal
muscle fibers (Sleigh et al., 2014).
The cytoplasmic tyrosyl-tRNA synthetase (YARS) is also linked
to CMT. In particular, the mutant substitutions G41R and E196K,
and deletion 153–156, are associated with dominant inter-
mediate Charcot-Marie-Tooth C (DI-CMTC) (Jordanova et al.,
2006). While the G41R and 153–156 mutations demonstrated
severe catalytic defects, the E196 mutant was more active, sug-
gesting that canonical activity defects are not responsible for
the disease phenotype (Froelich and First, 2011). Furthermore,
mutations are not found in domains responsible for previously
reported non-canonical functions such as the cytokine activity of
YARS (Wakasugi and Schimmel, 1999), suggesting that the CMT
pathogenic substitutions may not be associated with YARS non-
canonical activities. The mutated YARS enzyme exhibits stability
in vivo that is comparable to the wild type enzyme (Froelich and
First, 2011), but may be subject to a similar tendency to cellu-
lar mislocalization in neuroblastoma cells lines that was seen with
GARS (Jordanova et al., 2006).
The bifunctional (cytoplasmic and mitochondrial) lysyl-tRNA
synthetase (KARS) represents another targeted gene in CMT. One
interesting CMT patient was found to be a compound heterozy-
gote with mutations encoding both a L133H missense and a
Y173SX7-frame shift mutation (McLaughlin et al., 2010). Both
mutations localize to the anticodon-binding domain, however the
Y173SX7-frame shift likely results in complete loss of the catalytic
domain. The L113H catalytic analysis results showed a reduction
in aminoacylation to levels below 25% of wild type. In addition
to peripheral neuropathy, a behavioral pathology was observed
in this subject. KARS is also part of the multi-synthetase com-
plex (MSC) and can exist as either a dimer or tetramer. KARS
has additional non-canonical functions involved in signaling, cell
migration, and viral HIV infection, some of which are activated
by post-translational modification (Motzik et al., 2013). Mitogen-
activated kinase (MAPK) phosphorylation induces release of one
dimer from theMSC for translocation into the nuclease, while the
other dimer remains with the MSC to continue protein synthesis
(Ofir-Birin et al., 2013).
Another well characterized tRNA synthetase associated with
hereditary motor neuropathy is the cytosolic alanyl-tRNA syn-
thetase (AARS). In an earlier study, characterization of the mouse
strain AARSsti (or “sticky” mouse) with uncharacteristic CMT
phenotype, a progressive neurogeneration and a coat defect, sug-
gested a link between these properties and an editing defect
in AARS (Lee et al., 2006; Latour et al., 2010). Phenotypically,
the AARSsti mice have significant Purkinje cell loss and ubiq-
uitin inclusions suggestive of protein misfolding that are absent
in GARSNmf294/+ mice (Stum et al., 2011). Another genetic
investigation of AARS CMT2N subjects in an Australian family
showed additional symptoms that included sensorineural deaf-
ness (McLaughlin et al., 2012). An attractive hypothesis is that
the protein misfolding is a direct consequence of mistranslation
originating from the misacylation of tRNAAla with serine instead
of alanine (Guo et al., 2009).
Mutations in ARS genes have also been linked to non-CMT
peripheral neuropathies. Recently, a cytoplasmic histidyl-tRNA
synthetase (HARS) heterozygous mutation, R137Q, was found in
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a 54-year-old patient with peripheral neuropathy (Vester et al.,
2013). In yeast, the mutation encoded a loss of function substi-
tution in HARS, and the transfected mutant HARS gene failed
to support growth. When introduced in C. elegans, the mutant
HARS gene bearing the R137Q mutation caused aberrant motor
neuron axonal growth and a progressive loss of motor coordina-
tion. In a fashion reminiscent of the some of the GARS-linked
CMT mutants, the R137Q substitution eliminates a salt bridge
at the dimer interface with D64 of the opposite monomer (Xu
et al., 2012). This provides one scenario by which the R137Q
substitution could bring about a loss of function, and promote
the peripheral neuropathy phenotype. However, the existence of
a heterozygous asymptomatic carrier with the same mutation
suggests that the genetics of the system are not straightforward,
and may be confounded by incomplete penetrance effects. On
a related note, patients with late-onset CMT2 were identified
with mutations in the methionyl-tRNA synthetase (MARS) gene
(Gonzalez et al., 2013). The mutation affects a highly conserved
arginine residue, R618C, that forms a salt-bridge interaction at
the catalytic and anticodon-binding domain interface. Much like
with R137Q HARS, the R618C MARS phenotype is observed to
have a late onset, and does not show complete penetrance. Both
mutations cause a loss of function in yeast models.
AMINOACYL-tRNA SYNTHETASES AND SENSORINEURAL DISEASES
Sensorineural deafness is characterized by defects in either the
inner ear or the connecting auditory neural circuitry. Perrault
Syndrome is described clinically as an ovarian dysgenesis with
sensory hearing loss. Genetic studies indicate that mutations in
mitochondrial HARS2 and LARS2 are both linked to Perrault
Syndrome (Pierce et al., 2011, 2013). In the HARS2 gene, a com-
pound heterozygous mutation encoding both L200V and V368L
is linked to Perrault Syndrome, and these substitutions alter
highly conserved residues in the catalytic domain. Pyrophosphate
exchange assays demonstrated that the resulting mutant pro-
teins exhibit decreased activity, implying that the phenotype is a
straightforward loss of function effect likely arising from reduced
respiratory chain complex activity. Given the limitations of this
single assay, the mutant substitutions may have other struc-
tural and functional consequences. Similarly, the LARS2mutation
associated with Perrault Syndrome, T522N, also targets a highly
conserved residue located in the catalytic domain. By contrast, the
frame shift mutation at codon 360 (c.1077delT) and T629M com-
pound heterozygous mutations found in another Perrault syn-
drome patient localizes to the poorly conserved leucine-specific
C-terminal domain. Yeast complementation assays showed that
T522N LARS2 did not support growth, while T629M LARS2 did.
Notably, C. elegans models carrying the mutations were com-
pletely sterile, recapitulating at least one component of the disease
phenotype.
Cytoplasmic HARS has been also been associated with a
heterogeneous sensorineural disease that causes deaf-blindness
Usher Syndrome Type IIIB. Usher Syndrome is a polygenetic
disease with at least 11 different loci identified. Most of the
genes associated with Usher Syndrome are typically involved in
inner ear hair cell morphology and development (Yan and Liu,
2010). The three clinical subtypes are divided up by severity of
the symptoms and age of onset that the phenotype presents.
A homozygous mutation in HARS, Y454S, was discovered in
patients with Usher Syndrome IIIB (Puffenberger et al., 2012)
and is the first cytoplasmic HARS mutation associated with dis-
ease. In these patients hearing and vision are severely impaired
early in childhood, and fever induced hallucinations can occur.
While peripheral nerve function seems to be normal, there is
some mild trunk ataxia. The Y454S mutation, which is local-
ized specifically on the surface of the anticodon-binding domain
(ABD), juxtaposes the catalytic domain of the second monomer.
Y454 hydrogen-bonds with residue E439 within the anticodon
binding domain, and E439 is positioned to interact with K148
from the catalytic domain of the second monomer to form a salt-
bridge interaction (Xu et al., 2012)1. Initial aminoacylation data
employing wild type and mutant versions of the mouse enzyme
demonstrates that the Y454S substitution is unlikely to be a sim-
ple loss of function. Accordingly, current efforts are testing the
hypothesis that HARS has a secondary function that is impaired
by the Y454S substitution.
Hearing loss phenotypes have been linked to a number of
ARSs in addition to HARS. Patients in three unrelated consan-
guineous Pakistani families suffered from an autosomal recessive
non-syndromic hearing impairment (ARNSHI) linked to muta-
tions in KARS in the known ARNSHI-associated locus DFNB89
(Santos-Cortez et al., 2013). One of the mutations is predicted
to encode an Y173H substitution in a residue located in the
oligomer-binding (OB) fold motif of the KARS anticodon bind-
ing domain. In this location, the substitution could negatively
affect tRNA binding and/or catalysis. Significantly, the mouse
organ of Corti and vestibular system features many cell types,
including inner/outer hair cells spiral ligament, and sulcus and
spiral limbus cells of the vestibular membrane epithelium where
KARS is prominently expressed.
AMINOACYL-tRNA SYNTHETASES AND CENTRAL NERVOUS SYSTEM
DISEASES
In contrast to the peripheral nervous system and the sensoriner-
vous system, there are few reports linking ARSs to central nervous
system diseases, which often affect specific brain regions. The
autosomal recessive monogenetic disease Leukoencephalopathy
with Brain stem and Spinal cord involvement and elevated Lactate
(LBSL) represents the first well-characterized CNS disease associ-
ated with an ARS. Genetic analysis of some 30 different families
helped link the disease to mutations in the DARS2 gene encoding
mitochondrial AspRS (Scheper et al., 2007). Hallmarks of the dis-
ease defined by MRI imaging include abnormalities of the white
matter in the cerebellum, spinal cord, and brainstem. While the
mutant substitutions in LBSL are predicted to impair dimer for-
mation and decrease DARS2 catalytic function, mitochondrial
respiratory chain complex activity in these LBSL patients was
normal (Scheper et al., 2007).
Mutations in the DARS gene encoding cytoplasmic AspRS
were identified in patients with hypomyelination with brain stem
and spinal cord involvement and leg spasticity (HBSL), an inher-
ited white matter disease (Taft et al., 2013). These DARS coding
changes may affect enzyme activity by either disrupting tRNA
binding or reducing protein expression (Van Berge et al., 2012,
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2013). Interestingly, patients with the DARS-linked white matter
disease exhibited the same types of white matter abnormalities
in brain stem and spinal cord regions by MRI imaging that
were observed in patients with the DARS2 mutations linked to
LBSL. Cases of white matter disease associated with ARSs are
not exclusively restricted to AspRS. A recent report described a
disease called leukoencephalopathy with thalamus and brainstem
involvement and high lactate (LTBL) linked to mutations encod-
ing mitochondrial glutamyl-tRNA synthetase (EARS2) (Steenweg
et al., 2012). The full characterization of the role of ARS function
in these diseases is at an early stage, and it is too soon to conclude
that they are entirely explained by the sensitivity of neurons to
decreased output in translation.
Several other relatively recent reports highlight the potential
association of mutations in ARS genes with neurodegenerative
diseases. For example, the lethal heterogeneous neurodegener-
ative disease pontocerebellar hypoplasia (PCH6) was linked to
the RARS2 (mitochondrial arginyl-tRNA synthetase) gene in a
patient with a homozygous frameshift mutation predicted to
generate a truncated protein (Edvardson et al., 2007). Other
case studies of PCH6 subjects subsequently identified additional
RARS2 mutations (Glamuzina et al., 2012). In the zebrafish
model, RARS2 is highly expressed in the brain 24 h post fertiliza-
tion. Of further interest, zebrafish knockdownmodels of TSEN54
(subunit associated with RNA splicing previously described) and
RARS2 produce comparable phenotypes characterized by brain
hypoplasia and increased cell death, but little effect on brain pat-
terning. These interesting results suggest there may be a common
pathological PCH phenotype associated with loss of function of
the TSEN and RARS2 alleles, as well as a demand for specific
spliced tRNAs products at specified times during neuronal devel-
opment (Kasher et al., 2011). Recently, whole-exome sequencing
identified that QARS is a causative gene in affected individuals
of the two families with children affected by autosomal-recessive
primary microcephaly (MCPH) (Zhang et al., 2014). Symptoms
of this disease are associated with intellectual disability, seizures
during infancy, and atrophying in brain regions of the cerebel-
lar vermis and cerebral cortex. This disease phenotype is similar
to the PCH caused by mutations in RARS and TSEN complex
previously described. However, specific brain regions are differen-
tially affected for each disease. Four variants were identified, two
of which were localized to the catalytic domain and the remain-
ing two to the tRNA binding N-terminal domain. Activity studies
showed that all mutations caused a loss of functional protein.
Also, a zebrafish model demonstrated that QARS is essential for
proper eye and brain development.
The potential value of the zebrafish in studying ARS-linked
neurodegenerative diseases is suggested by another recent report
in which methionyl-tRNA synthetase (MARS) was identified in
an exome sequencing study as one of 15 genes linked to hered-
itary spastic paraplegias (HSP) (Novarino et al., 2014). HSP is
characterized by the degeneration and progressive loss of corti-
cospinal motor neuron tract function; patients typically present
with lower limb spasticity, seizures, ataxia, peripheral neuropathy,
intellectual disability, skin, and visual defects. The potential roles
of many of the genes reported in this study in HSP were validated
in the zebrafish model; the MARS mutation was too severe to be
fully evaluated.
Another important connection between ARS function and
neurodegenerative disease reported recently is the linkage
between the aminoacyl-tRNA synthetase complex interacting
multifunctional protein-2 (AIMP2, also referred to as p38) and
familial Parkinson’s disease. Initially, AIMP2 was reported to be
deposited in Lewy bodies, and its accumulation had been noted
in some familial cases of Parkinson’s disease (Corti et al., 2003;
Ko et al., 2005). Later, AIMP2 was determined to be a substrate
of the E3 ligase PARKIN. Multiple loss of function mutations
in the gene encoding PARKIN are a common cause of familial
Parkinson’s disease. While the complete basis of AIMP2-linked
neurological pathophysiology is not yet clear, it is possible that
an important secondary role of AIMP2 is modulating neuronal
protein turnover; when this process is dysfunctional, particular
cell death pathways (e.g., “parthanatos”) may become activated.
FUTURE PROSPECTS FOR THE ROLE OF tRNA IN HUMAN
DISEASE: THE ROLE OF SPATIAL AND TEMPORAL CONTROL
OF tRNA AND THE TRANSLATIONAL MACHINE IN DISEASE
PATHOPHYSIOLOGY
Given the emerging role of mRNA transport and localization in
neuronal function (Wang et al., 2007), it would not be surprising
if the temporal and spatial regulation of aminoacyl-tRNA syn-
thetases in neuronal compartments such as axons and dendrites
were not similarly important. Protein synthesis in these diverse
compartments clearly requires the full translational apparatus
in addition to the messenger RNA. At present, this remains an
underexplored area of tRNA and ARS biology, and a role for tRNA
and ARS in localized translation in neurons should be investi-
gated. Some of the models seeking to explain the link between the
ARS and CMT have proposed that themutant substitutions create
localization defects for the affected enzymes. As yet, the evidence
is not definitive, and the cellular mechanisms that traffic and
localize these enzymes are essentially unknown. Is the localization
of ARS enzymes to distal sites of the axon and dendrites depen-
dent on vesicular transport, tRNA, or other trafficking proteins?
In addition to the well-knownMulti-Synthetase Complex (MSC),
with what types of protein complexes are the ARS enzymes asso-
ciated, and what positions them at the site of local translation in
dendrites and neurons? Are there signaling pathways that are nec-
essary to initiate localization of ARS enzymes to these regions?
Furthermore, theremay bemechanisms in place (e.g., post- trans-
lational control) to spatially regulate the activity of ARS such that
tRNA is not aminoacylated until the proper cues are received to
synthesize proteins. These questions, and other issues related to
functional compartmentalization, should keep the role of tRNA
and ARS in complex human diseases as a major question for years
to come.
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